TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL‐2R signalling pathway
M Zhu, L Yang, X Shi, Z Gong, R Yu… - Journal of Cellular …, 2020 - Wiley Online Library
IL‐2R pathway is a key regulator in the development of immune cells and has emerged as a
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway
M Zhu, L Yang, X Shi, Z Gong, R Yu… - Journal of cellular …, 2020 - pubmed.ncbi.nlm.nih.gov
IL-2R pathway is a key regulator in the development of immune cells and has emerged as a
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.
M Zhu, L Yang, X Shi, Z Gong, R Yu… - Journal of Cellular …, 2019 - europepmc.org
IL‐2R pathway is a key regulator in the development of immune cells and has emerged as a
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
[HTML][HTML] TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL‐2R signalling pathway
M Zhu, L Yang, X Shi, Z Gong, R Yu… - Journal of Cellular …, 2020 - ncbi.nlm.nih.gov
IL‐2R pathway is a key regulator in the development of immune cells and has emerged as a
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL‐2R signalling pathway
M Zhu, Y Liu, X Shi, Z Gong, R Yu… - Journal of Cellular …, 2020 - search.proquest.com
IL‐2R pathway is a key regulator in the development of immune cells and has emerged as a
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL‐2R signalling pathway
M Zhu, Y Liu, X Shi, Z Gong, R Yu… - Journal of Cellular …, 2020 - search.proquest.com
IL‐2R pathway is a key regulator in the development of immune cells and has emerged as a
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …
promising drug target in cancer treatment, but there is a scarcity of related inhibitors. TPD7 is …